Primary CNS Lymphoma: Rituximab Addition to Methotrexate-Based Induction
A negative headline trial whose one positive subgroup is the age group she is not in, and a renal function that changes how the base regimen itself has to be dosed before the rituximab question is even worth arguing.
V.N., a 68-year-old retired librarian, spent forty years cataloguing a small-town collection she still visits weekly to help the current staff, and it was the staff who first noticed something wrong — she had started repeating questions she'd just asked and struggling mid-sentence for ordinary words. Her family dated the change to roughly six weeks before presentation, alongside a new unsteadiness in her gait that she'd attributed to a bad hip. An MRI ordered by her primary care physician showed a single periventricular, enhancing lesion; stereotactic biopsy confirmed diffuse large B-cell lymphoma, and HIV testing and systemic staging were both negative, establishing this as primary CNS lymphoma rather than secondary spread from a body cavity source. She lives independently, still drives locally, and until six weeks ago had no cognitive complaints at all — a genuinely healthy baseline against which this represents a sharp, recent decline rather than a slow one.
The induction question the team is actually arguing isn't methotrexate itself — high-dose methotrexate-based induction is the accepted backbone regardless of what else is added — it's whether to add rituximab. HOVON 105 (Bromberg and colleagues), the largest randomized trial to test this directly, found no benefit from adding rituximab to methotrexate-based induction in its primary event-free-survival endpoint, a result made more plausible by rituximab's own poor penetration across an intact blood-brain barrier. An unplanned subgroup analysis did find a signal — but specifically in patients aged 60 and under, and those were also the only patients the protocol consolidated with whole-brain radiation. V.N. is 68. She sits in the stratum where no signal appeared and where radiation is, in her case as in the trial, being deferred for neurotoxicity reasons — so the one piece of that trial pointing toward rituximab is the piece that describes someone else. Her baseline renal function, meanwhile, is its own separate fact the dossier already contains: an eGFR of 58, common enough at her age, but exactly the kind of number that changes how aggressively the methotrexate itself needs to be hydrated and monitored before anyone gets to argue about rituximab at all.
Multidisciplinary conference, induction planning
The trial that actually tested this — methotrexate-based induction with or without rituximab, followed by whole-brain radiation — found no difference in progression-free survival for the overall population, and rituximab's own pharmacology explains why: only a small fraction of serum concentration crosses an intact blood-brain barrier, so a large CNS treatment effect was never especially plausible to begin with. And I want to head off the subgroup argument before it's made: the one age stratum where a signal did appear was 60 and under, and that same stratum was the only one the protocol gave whole-brain radiation to. You can't detach the signal from the radiation, and either way it isn't her stratum. I'd omit it — real infusion-reaction risk and cost for a drug whose primary trial didn't clear its own bar.
You're right about the subgroup and I'm not going to argue it the other way — the signal is in the 60-and-under group, it strengthened with longer follow-up in that group, and she isn't in it. So I'm not claiming the trial supports rituximab for her. What I am claiming is narrower: HOVON 105 randomized 200 patients across an age range of 18 to 70, which leaves the over-60 stratum far too small to distinguish no benefit from a modest one. Absence of a signal in an underpowered stratum is not the same finding as a demonstrated absence of effect, and treating it as one is its own error.
Where I'll concede ground is on what that leaves me standing on. It isn't trial evidence — it's extrapolation from rituximab's established role in systemic CD20-positive large B-cell disease, plus the fact that most centers do give it here. That's a genuinely weaker argument than the one I'd have made if the subgroup had gone the other way, and I'd rather say so plainly than dress practice pattern up as evidence.
Both positions are reasonable and I don't think this case turns on resolving them today — it turns on something more immediate. Her eGFR of 58 means the methotrexate itself, the drug neither of you is debating, needs a modified hydration and urinary alkalinization protocol with serum-level checks at 24, 48, and 72 hours, and a glucarpidase-rescue plan on standby, before we get to argue about whether rituximab adds anything on top of it.
Getting the base regimen's clearance monitoring wrong in a patient with reduced renal function is a more probable, more severe harm than either answer to the rituximab question — I'd rather we spend the next ten minutes on that protocol than on a debate where reasonable people can genuinely land either way.
Agreed: methotrexate-based induction with rituximab added, run under the modified renal-clearance protocol with glucarpidase available if 48-hour levels run high, and whole-brain radiation held as a deferred consolidation option rather than a planned next step.
Not agreed: whether extrapolation is enough. Both physicians accepted that HOVON 105's age subgroup argues against rituximab in her specifically, not for it, and the plan was written on that understanding rather than around it. What they could not settle is what follows from an over-60 stratum too small to separate no benefit from a small one — the pharmacologist reads an untested drug in her age group as a reason to omit it, the neuro-oncologist reads it as a reason the question stays open. Neither position was overruled; the team recorded the rationale in the chart as extrapolation from systemic disease and prevailing practice, deliberately not as trial evidence, so that whoever reads it next inherits the weakness of the argument along with the decision.